{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:47:10Z","timestamp":1788011230236,"version":"build-2784847793"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.htct.2025.103822","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T17:23:29Z","timestamp":1746811409000},"page":"103822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Diagnosis and treatment of chronic lymphocytic leukemia: 2025 recommendations of the Brazilian Group of Chronic Lymphocytic Leukemia of the Brazilian Association of Hematology and Hemotherapy (ABHH)"],"prefix":"10.1016","volume":"47","author":[{"given":"Carlos S\u00e9rgio","family":"Chiattone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda de Morais","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Buccheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihoko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Costa","family":"Fortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura Rosane Valerio","family":"Ikoma-Colturato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Hamerschlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera Lucia de Piratininga","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talita Maira Bueno","family":"da Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani","family":"Laks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rony","family":"Schaffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolney Gois","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Scheliga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Amoedo","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir Kanaan","family":"Nabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Dezen","family":"Gaiolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus Vescovi","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle Le\u00e3o Cordeiro","family":"de Farias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glaciano","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Pitombeira","family":"de Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6395-6849","authenticated-orcid":false,"given":"Celso","family":"Arrais-Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.htct.2025.103822_bib0001","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bjhh.2016.07.004","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia","volume":"38","author":"Rodrigues","year":"2016","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"1","key":"10.1016\/j.htct.2025.103822_bib0002","first-page":"80","article-title":"Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia","volume":"25","author":"Diehl","year":"1998","journal-title":"Semin Oncol"},{"issue":"23","key":"10.1016\/j.htct.2025.103822_bib0003","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2010-05-286500","article-title":"Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance","volume":"116","author":"Moreno","year":"2010","journal-title":"Blood"},{"issue":"5\u20136","key":"10.1016\/j.htct.2025.103822_bib0004","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/10245330400018599","article-title":"Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia","volume":"9","author":"Robak","year":"2004","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.htct.2025.103822_bib0005","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3324\/haematol.2015.136556","article-title":"Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia","volume":"101","author":"Strati","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.htct.2025.103822_bib0006","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/ejh.14389","article-title":"Central nervous system involvement in chronic lymphocytic leukemia: a case-series","volume":"114","author":"Hyppolito","year":"2025","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.htct.2025.103822_bib0007","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.htct.2023.05.006","article-title":"Infections in patients with chronic lymphocytic leukemia","volume":"45","author":"Guaran\u00e1","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"issue":"7","key":"10.1016\/j.htct.2025.103822_bib0008","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.htct.2025.103822_bib0009","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJMoa0806122","article-title":"B-cell clones as early markers for chronic lymphocytic leukemia","volume":"360","author":"Landgren","year":"2009","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.htct.2025.103822_bib0010","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1182\/blood.2023023797","article-title":"New signature predicts MBL-to-CLL progression","volume":"143","author":"Rosenquist","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.htct.2025.103822_bib0011","first-page":"1640","article-title":"The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL","volume":"8","author":"Matutes","year":"1994","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.htct.2025.103822_bib0012","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.htct.2025.103822_bib0013","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.htct.2025.103822_bib0014","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2141.2008.07086.x","article-title":"The prognostic significance of cytopenia in chronic lymphocytic leukaemia\/small lymphocytic lymphoma","volume":"141","author":"Zent","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.htct.2025.103822_bib62","first-page":"252","article-title":"Prognostic factors in chronic lymphocytic leukemia","volume":"24","author":"Rai","year":"1987","journal-title":"Semin Hematol"},{"issue":"6","key":"10.1016\/j.htct.2025.103822_bib0015","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.htct.2025.103822_bib0016","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bjh.13788","article-title":"CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status","volume":"172","author":"Baumann","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.htct.2025.103822_bib0017","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.htct.2025.103822_bib0018","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hon.2661","article-title":"Distinctive IGHV gene usage and stereotyped receptors in South American patients with chronic lymphocytic leukemia","volume":"37","author":"Stanganelli","year":"2019","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1016\/j.htct.2025.103822_bib0019","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41375-022-01604-2","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL","volume":"36","author":"Agathangelidis","year":"2022","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.htct.2025.103822_bib0020","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.htct.2025.103822_bib0021","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1200\/JCO.2010.32.0838","article-title":"Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial","volume":"29","author":"Gonzalez","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.htct.2025.103822_bib0022","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-08-1630","article-title":"The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.htct.2025.103822_bib0023","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","article-title":"Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial","volume":"114","author":"Zenz","year":"2009","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.htct.2025.103822_bib0024","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.htct.2025.103822_bib0025","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1200\/jco.2015.33.15_suppl.7002","article-title":"The international prognostic index for patients with CLL (CLL-IPI): an international meta-analysis","volume":"33","author":"Kutsch","year":"2015","journal-title":"J Clin Oncol."},{"issue":"6","key":"10.1016\/j.htct.2025.103822_bib0026","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.htct.2025.103822_bib0027","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.12887","article-title":"Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and aso IgH RQ-PCR","volume":"166","author":"Raponi","year":"2014","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.htct.2025.103822_bib0028","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/leu.2009.140","article-title":"Standardized MRD flow and aso IgH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis","volume":"23","author":"B\u00f6ttcher","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.htct.2025.103822_bib0029","first-page":"1106","article-title":"Euroflow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"23","author":"van Dongen","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.htct.2025.103822_bib0030","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/leu.2015.313","article-title":"A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European research initiative on CLL study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.htct.2025.103822_bib0031","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.htct.2025.103822_bib0032","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.htct.2025.103822_bib0033","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.htct.2025.103822_bib0034","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1532-5415.1995.tb06377.x","article-title":"Validation of the cumulative illness rating scale in a geriatric residential population","volume":"43","author":"Parmelee","year":"1995","journal-title":"J Am Geriatr Soc"},{"issue":"24","key":"10.1016\/j.htct.2025.103822_bib0035","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"issue":"9747","key":"10.1016\/j.htct.2025.103822_bib0036","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.htct.2025.103822_bib0037","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.htct.2025.103822_bib0038","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.2023020158","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.htct.2025.103822_bib0039","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2008.17.2619","article-title":"Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Foon","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.htct.2025.103822_bib0040","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.htct.2025.103822_bib0041","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V124.21.19.19","volume":"124","author":"Eichhorst","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.htct.2025.103822_bib0042","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.htct.2025.103822_bib0043","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5\u2009years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.htct.2025.103822_bib0044","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1200\/JCO.2021.39.15_suppl.7523","article-title":"Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"39","author":"Barr","year":"2021","journal-title":"JCO"},{"issue":"10","key":"10.1016\/j.htct.2025.103822_bib0045","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.htct.2025.103822_bib0046","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.htct.2025.103822_bib0047","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"10232","key":"10.1016\/j.htct.2025.103822_bib0048","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"31","key":"10.1016\/j.htct.2025.103822_bib0049","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus Ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.htct.2025.103822_bib0050","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.htct.2025.103822_bib0051","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/JCO.22.00510","article-title":"Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial","volume":"41","author":"Hillmen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.htct.2025.103822_bib0052","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.htct.2025.103822_bib0053","doi-asserted-by":"crossref","first-page":"E387","DOI":"10.1002\/ajh.27110","article-title":"A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"98","author":"Kittai","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.htct.2025.103822_bib0054","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.htct.2025.103822_bib0055","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.htct.2025.103822_bib0056","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.htct.2025.103822_bib0057","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.htct.2025.103822_bib0058","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood-2015-08-634816","article-title":"Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.htct.2025.103822_bib0059","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/PPO.0000000000000533","article-title":"Management of chronic lymphocytic leukemia in less-resourced countries","volume":"27","author":"Chiattone","year":"2021","journal-title":"Cancer J"},{"issue":"8","key":"10.1016\/j.htct.2025.103822_bib0060","doi-asserted-by":"crossref","first-page":"E171","DOI":"10.1002\/ajh.24779","article-title":"Chronic lymphocytic leukemia in Brazil: a retrospective analysis of 1903 cases","volume":"92","author":"Gon\u00e7alves","year":"2017","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.htct.2025.103822_bib0061","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/jha2.444","volume":"3","author":"Pfister","year":"2022","journal-title":"EJHaem"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137925000902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137925000902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:09:30Z","timestamp":1749654570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137925000902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2531137925000902"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2025.103822","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and treatment of chronic lymphocytic leukemia: 2025 recommendations of the Brazilian Group of Chronic Lymphocytic Leukemia of the Brazilian Association of Hematology and Hemotherapy (ABHH)","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2025.103822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular.","name":"copyright","label":"Copyright"}],"article-number":"103822"}}